ArticleActa endocrinologica (Bucharest, Romania : 2005)
LEVELS OF COPEPTIN AND BETA-HYDROXY BUTYRATE IN DIABETIC KETOACIDOSIS.
Article in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetic ketoacidosis (DKA) is an acute complication of diabetes mellitus, characterized by hyperglycemia, ketosis, and metabolic acidosis. This study aimed to evaluate blood and urine levels of copeptin and β-OHB in patients with DKA. Patients and methods: 49 patients with DKA and 30 healthy controls were included in the study. Serum and urine β-OHB and copeptin levels were measured using ELISA. Statistical analysis included Mann-Whitney U test, t-test, and ROC curve analysis to assess diagnostic performance. Results: Compared with controls, patients with DKA demonstrated significantly higher serum and urine β-OHB levels (p < 0.001) and lower serum copeptin levels (p < 0.001), while urine copeptin did not differ significantly (p = 0.456). Serum copeptin showed high sensitivity (98.0%) but limited specificity, whereas urine copeptin had low diagnostic value. Discussion: This study confirms β-OHB as a reliable biomarker for diagnosing DKA, with urine β-OHB offering a rapid and non-invasive alternative. Copeptin did not demonstrate diagnostic discrimination between DKA and healthy subjects. Conclusion: Quantitative measurement of serum and urine β-OHB provides superior diagnostic accuracy in DKA and should be incorporated into emergency diagnostic pathways. Copeptin may complement β-OHB in monitoring fluid status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.